{
  "_metadata": {
    "version": "2.0",
    "ticker": "NUVL",
    "company_name": "Nuvalent",
    "data_source": "Nuvalent Corporate Presentation January 12, 2026",
    "extraction_date": "2026-02-04"
  },
  "ticker": "NUVL",
  "name": "Nuvalent",
  "company": {
    "name": "Nuvalent",
    "ticker": "NUVL",
    "exchange": "NASDAQ",
    "headquarters": "Cambridge, MA",
    "website": "https://nuvalent.com",
    "one_liner": "Developing best-in-class TKIs for ROS1+ and ALK+ NSCLC with TRK-sparing selectivity to address resistance and CNS activity limitations of current therapies"
  },
  "investment_thesis_summary": {
    "core_thesis": "Nuvalent is developing next-generation kinase inhibitors designed to overcome the key limitations of approved ROS1 and ALK TKIs - resistance mutations, CNS penetration, and TRK-related toxicity. With zidesamtinib's PDUFA date of September 18, 2026 and neladalkib NDA submission planned for 1H 2026, the company has two potential near-term commercial assets in validated oncology markets.",
    "key_value_drivers": [
      "Zidesamtinib PDUFA September 18, 2026 - first TRK-sparing ROS1 inhibitor",
      "Neladalkib NDA submission 1H 2026 - addresses lorlatinib-resistant ALK mutations",
      "Best-in-class preclinical selectivity profiles vs competitors",
      "~$1.4B cash runway into 2029"
    ]
  },
  "investment_analysis": {
    "bull_case": [
      "Zidesamtinib and neladalkib TRK-sparing design addresses major safety limitation of competitors",
      "Exceptional durability data: 93% DOR \u226518 months for zidesamtinib 1 prior TKI; 60% DOR \u226518 months for neladalkib TKI pre-treated",
      "Dual programs de-risk company - success in either ROS1 or ALK creates substantial value",
      "Strong CNS activity addresses critical unmet need (50%+ of patients develop brain mets)",
      "Clean safety profile with low discontinuation rates (2% zidesamtinib, 5% neladalkib)"
    ],
    "bear_case": [
      "Repotrectinib and taletrectinib already approved with established market presence in ROS1",
      "Lorlatinib 1L data (mPFS not reached at 60 months) sets high bar for ALK",
      "Commercial execution risk for a first-time launch organization",
      "NVL-330 HER2 program still early (Phase 1) with significant competition"
    ],
    "key_debates": [
      {
        "question": "Can TRK-sparing differentiation drive meaningful market share vs established competitors?",
        "bull_view": "CNS toxicity with TRK inhibitors is treatment-limiting; physicians will prefer cleaner profile",
        "bear_view": "Efficacy trumps safety in oncology; repotrectinib already has strong data",
        "what_resolves_it": "Real-world uptake post-launch and head-to-head comparisons"
      }
    ]
  },
  "pipeline_summary": {
    "total_programs": 3,
    "clinical_stage": 3,
    "programs": [
      {
        "asset": "zidesamtinib",
        "target": "ROS1",
        "stage": "NDA Filed",
        "indications": "ROS1+ NSCLC",
        "ownership": "Wholly-owned",
        "next_catalyst": "PDUFA September 18, 2026"
      },
      {
        "asset": "neladalkib",
        "target": "ALK",
        "stage": "Phase 2 (NDA planned 1H 2026)",
        "indications": "ALK+ NSCLC, ALK+ solid tumors",
        "ownership": "Wholly-owned",
        "next_catalyst": "NDA submission 1H 2026"
      },
      {
        "asset": "NVL-330",
        "target": "HER2",
        "stage": "Phase 1",
        "indications": "HER2+ NSCLC and solid tumors",
        "ownership": "Wholly-owned",
        "next_catalyst": "Phase 1 dose escalation ongoing"
      }
    ]
  },
  "platform": {
    "name": "Structure-guided kinase inhibitor design",
    "description": "Nuvalent's platform leverages deep structural biology expertise to design kinase inhibitors with optimized selectivity profiles, specifically engineering out TRK activity while maintaining potent target inhibition and CNS penetration."
  },
  "financials": {
    "cash_position": "~$1.4B (unaudited, YE 2025)",
    "cash_runway": "Into 2029"
  },
  "leadership": {
    "ceo": "James Porter, PhD",
    "team_experience": "12 prior FDA approvals across leadership team"
  },
  "market_opportunity": {
    "ros1_nsclc": {
      "us_prevalence": "3,000-4,500 patients annually",
      "us_peak_sales": "$570M-$855M",
      "global_prevalence": "10,000-15,000 patients annually"
    },
    "alk_nsclc": {
      "us_prevalence": "~9,000 patients annually",
      "us_peak_sales": "$1.35B-$2.0B",
      "global_prevalence": "30,000-45,000 patients annually"
    }
  },
  "market_cap": "$7.3B"
}